Acumen Pharmaceuticals Inc ABOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABOS is a good fit for your portfolio.
News
-
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
-
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
-
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
-
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
-
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
-
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Trading Information
- Previous Close Price
- $2.37
- Day Range
- $2.26–2.39
- 52-Week Range
- $1.81–11.31
- Bid/Ask
- $2.31 / $2.40
- Market Cap
- $138.78 Mil
- Volume/Avg
- 264,216 / 365,953
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.acumenpharm.com
Comparables
Valuation
|
Metric
|
ABOS
|
CTIC
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.53 | — | 2.30 |
Price/Sales | — | 14.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ABOS
CTIC
TYRA
Financial Strength
|
Metric
|
ABOS
|
CTIC
|
TYRA
|
|---|---|---|---|
Quick Ratio | 29.83 | 1.20 | 43.88 |
Current Ratio | 30.20 | 1.27 | 44.83 |
Interest Coverage | — | −3.20 | — |
Quick Ratio
ABOS
CTIC
TYRA
Profitability
|
Metric
|
ABOS
|
CTIC
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −19.28% | −46.52% | −21.92% |
Return on Equity (Normalized) | −21.04% | — | −23.10% |
Return on Invested Capital (Normalized) | −24.75% | −143.40% | −27.33% |
Return on Assets
ABOS
CTIC
TYRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Pwfgxjvv | Qdh | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jxhdcgn | Tdckt | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ngbsmnf | Dxqtvy | $114.0 Bil | |||
| Moderna Inc
MRNA
| Qgvyrjwp | Lxf | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xrgtvmcr | Swvqwy | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Tmyykjsr | Mkv | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Nxgsykdm | Xlvn | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gzqypmjl | Vywzkt | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Zhbspgnh | Ljvq | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Dhykzsrgb | Jcpyvny | $11.6 Bil |